A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the beta(3) Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Sender Herschorn, Jack Barkin, David Castro-Diaz, Jeffrey M. Frankel, Montserrat Espuna-Pons, Angelo E. Gousse, Matthias Stoelzel, Nancy Martin, Adrie Gunther, Philip Van Kerrebroeck

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)313-320
JournalUrology
Volume82
Issue number2
DOIs
Publication statusPublished - Aug 2013

Cite this